State Tele-Buprenorphine Prescribing Policies by Medical Professional Type

Why It Matters

State-level barriers may prevent Medicaid patients from accessing proven tele‑buprenorphine treatment, limiting the effectiveness of a federal effort to expand virtual OUD care nationwide.

Key Takeaways

• 32 states allow Medicaid tele‑buprenorphine for physicians, NPs, and PAs
• 12 states restrict virtual prescribing to physicians only
• 6 states require an in‑person evaluation before tele‑buprenorphine
• Federal DEA proposal could standardize virtual prescribing nationwide
• Policy gaps risk uneven treatment access for Medicaid patients

Pulse Analysis

The opioid use disorder epidemic continues to claim tens of thousands of American lives each year, and buprenorphine remains the gold‑standard medication for long‑term recovery. Since the pandemic‑era suspension of the Ryan Haight Act’s in‑person requirement, tele‑buprenorphine has demonstrated higher retention rates and broader geographic reach, especially for Medicaid enrollees who often face transportation and stigma hurdles. This shift has sparked a national conversation about making virtual prescribing a permanent fixture in OUD treatment.

A comprehensive legal mapping by RAND researchers shows that state Medicaid policies are far from uniform. Thirty‑two states have embraced the tele‑buprenorphine model for physicians, nurse practitioners and physician assistants, while a dozen restrict it to physicians alone, and six still mandate an initial face‑to‑face visit. These disparities create a patchwork of access, where a patient’s ability to receive medication without leaving home depends on the state they reside in. For providers, navigating divergent regulations adds administrative complexity and can deter the adoption of telehealth workflows.

Against this backdrop, the Drug Enforcement Administration’s proposed rulemaking seeks to carve out a federal registration pathway that would allow fully virtual OUD care nationwide, provided state law permits it and safeguards are in place. If enacted, the rule could harmonize standards, reduce compliance burdens, and expand treatment capacity across the Medicaid population. However, the success of the initiative will hinge on how quickly states align their statutes with the federal framework, ensuring that policy gaps do not undermine the promise of broader, equitable access to life‑saving medication.